Dan Groman - 17 Oct 2023 Form 4 Insider Report for Enfusion, Inc.

Role: Chief Technology Officer
Signature: /s/ Matthew Campobasso, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 17 Oct 2023
Net transactions value: -$45,450
Form type: 4
Filing time: 19 Oct 2023, 16:15:59 UTC
Previous filing: 21 Sep 2023
Next filing: 16 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENFN	Class A Common Stock	Sale	$45,450	-5,000	-3.5%	$9.09	138,828	17 Oct 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on June 15, 2023.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.16. Full information regarding the number of shares sold at each separate price will be furnished to the SEC staff upon request.